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Background: The Gibberellin Stimulated-Like (GSL) or Snakin peptides from higher plants are cysteine-rich, with
broad spectrum activity against a range of bacterial and fungal pathogens. To detect GSL peptides in applications
such as western blot analysis and enzyme-linked immunosorbent assays (ELISA), specific antibodies that recognise
GSL peptides are required. However, the intrinsic antimicrobial activity of these peptides is likely to prevent their
expression alone in bacterial or yeast expression systems for subsequent antibody production in animal hosts.
Results: To overcome this issue we developed an Escherichia coli expression strategy based on the expression of
the GSL1 peptide as a His-tagged thioredoxin fusion protein. The DNA sequence for the mature GSL1 peptide from
potato (Solanum tuberosum L.) was cloned into the pET-32a expression vector to produce a construct encoding
N-terminally tagged his6-thioredoxin-GSL1. The fusion protein was overexpressed in E. coli to produce soluble
non-toxic protein. The GSL1 fusion protein could be easily purified by using affinity chromatography to yield ~1.3 mg
of his6-thioredoxin-GSL1 per L of culture. The fusion protein was then injected into rabbits for antibody production.
Western blot analysis showed that the antibodies obtained from rabbit sera specifically recognised the GSL1 peptide
that had been expressed in a wheat germ cell-free expression system.
Conclusion: We present here the first report of a GSL1 peptide expressed as a fusion protein with thioredoxin that
has resulted in milligram quantities of soluble protein to be produced. We have also demonstrated that a wheat
germ system can be used to successfully express small quantities of GSL1 peptide useful as positive control in
western blot analysis. To our knowledge this is the first report of antibodies being produced against GSL1 peptide.
The antibodies will be useful for analysis of GSL1peptides in western blot, localization by immunohistochemistry
(IHC) and quantitation by ELISA.
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Small antimicrobial peptides are popular targets for en-
gineering plants in order to confer resistance to a range
of microbial diseases [1-5]. The Gibberellin Stimulated-
Like (GSL) peptides GSL1 and GSL2 (also known as
Snakin-1 and Snakin-2 [6]) are one such group. They are
cysteine-rich peptides from potato (Solanum tuberosum
L.) (Figure 1) that have been shown to have antimicro-
bial activity against a wide range of bacteria and fungi
[7-11], as well as nematodes [12]. GSL peptides are also
considered to be important in plant developmental* Correspondence: philippa.barrell@plantandfood.co.nz
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article, unless otherwise stated.processes such as cell division, and stress responses
regulating redox homeostasis [13,14]. This is supported
by the failure to recover viable plants following potato
transformation with antisense constructs of GSL genes
[6]. In contrast, over expression of GSL genes in potato
does not cause obvious changes in plant phenotype [15].
GSL peptides have a very similar spectrum of activity
against microbes [8,9]. They induce rapid aggregation of
both Gram-negative and Gram-positive bacteria, and al-
though this response does not correlate directly with
antimicrobial activity, it may play an in vivo role in con-
trolling pathogen migration [7,9,11]. Transgenic plants
over-expressing GSL genes have been shown to have in-
creased resistance to a range of microbial pathogens
[3,15-17].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 The DNA and amino acid sequence of the mature GSL1 (Genbank accession FJ195646) from Solanum tuberosum, after
cleavage of the N-terminal signal sequence. Restriction endonuclease recognition sites for EcoRI added for cloning purposes are indicated in
lower case letters.
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processed to yield a mature protein [8,9] (Figure 1). To
determine a protein’s expression pattern by western blot,
localization by immunohistochemistry (IHC) and quanti-
tation by ELISA, antibodies that selectively identify the
protein of interest are required. Antibodies are routinely
generated by injection of the protein (antigen) into a
host animal such as rabbit or mouse. After a number of
weeks, sera obtained from the host animal can then be
tested for the presence of antibodies that selectively rec-
ognise the antigen. To elicit an immune response in the
host animal, it is generally desirable to inject milligram
quantities of the antigen. Escherichia coli–based bacter-
ial expressions systems are commonly used to generate
such recombinant proteins [18].
The intrinsic antimicrobial activity of antimicrobial
peptides may prevent their expression in E. coli [19].
However, several proteins and peptides have been shown
to be successful as fusion partners with antimicrobial
peptides to enable their expression in E. coli [20-22].
The fusion protein is thought to protect the peptide
from proteolytic cleavage and block the peptide’s anti-
microbial activity against the expression host [23]. GSL1
has previously been expressed in E. coli by N-terminally
tagging the peptide with the 22 amino acid pelB leader
sequence enabling secretion into the bacterial periplas-
mic space [11]. However, to enable antibody production
it is recommended that small peptides be coupled to a
carrier protein to elicit a good immune response [24].
We have previously shown the utility of using thiore-
doxin as a fusion partner with an antimicrobial peptide
to produce recombinant protein in E. coli for antibody
production [25]. We chose the expression vector pET-
32a to generate N-terminally tagged his6-thioredoxin-
mature GSL1 fusion protein. The recombinant fusion
protein was non-toxic to the host bacterium E. coli and
protein was recovered in a soluble form. Sufficient re-
combinant GSL1 fusion protein was isolated and puri-
fied from E. coli in soluble form for injection into
rabbits. Antibodies were obtained from rabbit sera that
selectively recognised synthetic GSL1 in western blotanalysis of GSL1 peptide produced in a wheat germ
cell-free expression system. Our work is the first report
on the successful soluble expression of recombinant
GSL1 fusion protein and the generation of anti-GSL1
antibodies.
Results
Overexpression of the his6-thioredoxin-GSL1 fusion
protein in E. coli
The his6-thioredoxin-GSL1 fusion protein was overex-
pressed in the E. coli strain BL21 (DE3) using the pET-
32a vector. In comparison with thioredoxin alone
(Figure 2A, lanes 5-7, right arrow), very little GSL1–
thioredoxin fusion protein was expressed (Figure 2A,
lanes 2–4), as judged by Coomassie staining (Figure 2A,
left arrow). However, western blot analysis using anti-
thioredoxin antibodies showed that fusion protein of
expected molecular weight of approximately 27 kDa was
expressed for pET-32a+GSL1 (Figure 2B, left arrow,
lanes 2–4). Maximum production of the fusion protein
was achieved within 2 h (Figure 2B lane 3), without any
apparent toxicity to the bacteria. Sufficient GSL1 fusion
protein was judged to be produced in the soluble frac-
tion after cell lysis to proceed with purification on a
larger scale.
Purification of his6-thioredoxin-GSL1 fusion protein and
generation of antibodies in rabbits
We successfully employed an IMAC purification process
utilising the metal-binding polyhistidine (His.Tag) pre-
sent as part of the thioredoxin fusion protein. The GSL1
fusion protein was purified to high purity. Figure 3A
shows SDS-PAGE analysis by Coomassie staining of
purified GSL1 fusion protein through the IMAC column
purification process. Lane 1 shows protein fractions un-
bound by the column (flow through); Lane 2 shows the
eluate after the first wash showing many non-specific
protein bands; and Lanes 3-9 show the fractions after
elution buffer was applied. The arrow indicates the
GSL1 fusion protein, with the majority of the fusion pro-
tein eluting in fractions 5 and 6. Western blot analysis
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Figure 2 SDS-PAGE and western blot analysis of N-terminally tagged his6-thioredoxin GSL1 peptide expressed in E. coli. A. SDS-PAGE
analysis of the induced expression of his6-thioredoxin-GSL1 (Lanes 2–4 are 0, 2 and 4 hours) , and his6-thioredoxin tag only (Lanes 5-7 are 0, 2
and 4 hours). The expected size for his6-thioredoxin alone was approximately 23 kDA, and 30 kDa for N-terminally tagged his6-thioredoxin GSL1.
Lane 1 contains molecular weight standards. An arrow indicates each expressed protein band. B. Western blot analysis of the same fractions using
an anti-thioredoxin antibody.
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cessful purification of protein after elution from the
column (Figure 3B, arrow). It was estimated that ap-
proximately 1.3 mg of purified concentrated fusion pro-
tein was obtained per litre of bacterial culture. The
soluble fusion protein obtained was used for injection
into two rabbits. Three sub-cutaneous injections of ap-
proximately 0.3 mg of fusion protein in a volume of
500 μL per injection were made four weeks apart. Total
sera were collected two weeks after the final injection.
Wheat germ cell-free expression of his6-GSL1 to confirm
potency of anti-GSL antibody sera
In order to confirm the specificity of the anti-GSL1 anti-
bodies, GSL1 peptide was required as positive controls.
We purchased commercially synthesised mature GSL1
peptide to use as positive controls in our experiments.
We attempted to solubilise the peptide in water; acetic
acid; SDS loading buffer; SDS loading buffer +2- mer-
captoethanol; isopropanol; methanol; ethanol; aceto-
nitrile; trifluoroactic acid; and DMSO (data not shown).
However, it was not possible to solubilise the supplied
lyophilised peptide. Instead we cloned the DNA se-
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Figure 3 SDS-PAGE and western blot analysis of protein fractions from
analysis of the fractions obtained. Lane 1: flow through from column; lane
applied. The arrow indicates the GSL1 fusion protein. B: Western blot analygerm cell-free expression vector. The GSL1 cDNA se-
quence was cloned into the pEU-DEST vector [26]. Ex-
pression of the GSL1 construct resulted in translated
GSL1 protein, as judged by western blot analysis using
poly-His antibodies (data not shown).
Figure 4 shows Coomassie staining (A) and western
blot analysis (B) of total protein from the wheat germ
cell-free system. The vector control is shown in Lane 1,
with Lane 2 containing the GSL1 protein. Western blot
analysis was performed with total sera obtained from a
rabbit injected with the GSL1 fusion protein. Using a di-
lution of the resulting total sera of 1:400 and 1:100,000
goat anti-rabbit conjugated to horseradish peroxidase,
developed using peroxide and luminol/enhancer, anti-
bodies successfully recognised the synthesised GSL1
(Figure 4B, arrow). The western blot shows that the sera
obtained contained selective antibodies against the GSL1
peptide.
Discussion
We have successfully demonstrated that the antimicro-
bial GSL1 peptide can be expressed as a thioredoxin fu-
sion protein in a bacterial system to produce milligram
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the IMAC purification of his6-thioredoxin-GSL1. A: SDS-PAGE
2: eluate after first wash; lanes 3-9, fractions after elution buffer was
sis of the same protein fractions using an anti-thioredoxin antibody.
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Figure 4 SDS-PAGE and western blot analysis of wheat germ
cell-free expressed GSL1. A: Coomassie stained fractions.
B: Western blot analysis using total sera raised against the GSL1
fusion protein. Lane 1: no expression control; Lane 2: his6-GSL1.
The arrow in panel B indicates the GSL1 peptide.
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strain BL21 (DE3) using the pelB leader sequence to fa-
cilitate localization to the periplasmic space [11]. How-
ever, the protein produced was insoluble indicating
protein misfolding. In contrast, our N-terminally his6-
thioredoxin tagged mature GSL1 fusion protein was
found in the soluble cytoplasmic fraction when
expressed in the same E. coli strain. Thioredoxin has
previously been reported to be a useful partner for
expressing cysteine-rich proteins [18]. As GSL peptides
are highly cysteine-rich, this may also account for our
successful production of soluble fusion protein. Whilst
the GSL1 fusion protein was not expressed at the same
high level as the thioredoxin fusion protein alone
(Figure 2), milligram quantities of fusion protein could
be IMAC purified in large culture volumes (Figure 3).
This provided sufficient antigen for subsequent injection
into rabbits to elicit a rabbit immune response and
generate sera.
When it came to testing the potency of the anti-GSL1
sera it was not possible to use synthetically produced
GSL1 peptide due to its lack of solubility. This is likely
due to the structural nature of the peptides as GSL1possesses 12 conserved cysteine residues [8,9,27] which
would severely hamper the correct folding of a synthet-
ically produced peptide. Instead we turned to a wheat
germ cell-free expression system to generate N-
terminally his6-tagged version of the GSL peptide as
positive controls for western blot analysis. GSL1 was
successfully translated in the wheat-germ cell free ex-
pression system and the anti-GSL1 serum was shown to
selectively recognise the peptide (Figure 4). In addition,
the GSL1 antibodies raised against protein that was
expressed in the E. coli system were able to detect GSL1
peptides expressed in the plant-based wheat germ ex-
pression system. This highlights the robustness of using
thioredoxin as a carrier molecule and the specificity of
the antibodies raised against GSL1.
Some additional bands of higher molecular weight
were detected by the anti-GSL1 serum in the wheat
germ cell-free system in the western blot (Figure 4B).
Because the western blot analysis was performed with
total sera, and not purified antibodies, it is not surprising
to see cross reactive bands, as the rabbit may have en-
countered wheat-based proteins in its diet to which it
had produced antibodies. Most importantly, however, is
our observation that only lane 2 (Figure 4B, arrow) cor-
responding to the wheat germ extract containing GSL1
peptide showed any reactivity of the correct size ex-
pected for the GSL1 peptide alone, while the control
lane (1) was empty at the corresponding position.
We also used the DNA sequence for GSL2 [9] using
the same strategy as described in this paper for the gen-
eration of soluble thioredoxin-GSL2 fusion protein, and
immunisation of rabbits. However, we were unable to
generate soluble GSL2 peptide using the same wheat-
germ cell free expression system (data not shown). Com-
mercially sourced GSL2 peptide was also not able to be
solubilised in our hands. Therefore, with no positive
control GSL2 peptide, we were unable to ascertain
whether the sera obtained contained antibodies specific
to GSL2. We were able to determine that sera generated
from rabbit injected with his6-thioredoxin-GSL2 had no
reactivity against the GSL1 peptide produced in the
wheat-germ cell free expression system (data not shown).
These observations highlight the difficulty in working
with GSL peptides.
Although it was not attempted in our study, an add-
itional advantage of our production of the soluble GSL1
thioredoxin fusion protein could be through using the
thrombin and enterokinase protein cleavage sites present
in the pET-32a vector. These cleavage sites lie between
the end of the thioredoxin coding region and the GSL1
coding region. Separation of the GSL1 peptide from
thioredoxin in the GSL1 fusion protein could be
attempted by cleaving the fusion protein using thrombin
and enterokinase enzymes. This could then be used to
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or X-ray crystallography.
Conclusions
We present here the first report of a robust method for
the generation of GSL1 peptide expressed as a fusion
protein with thioredoxin that has resulted in milligram
quantities of soluble protein. We were able to demon-
strate that a wheat germ cell-free system can be used to
successfully express small quantities of GSL1 peptide
useful as positive control in western blot analysis. The
antibodies generated in rabbit after immunisation with
the GSL1 fusion protein expressed in a prokaryotic bac-
terial system were able to recognise the GSL1 peptide
produced in the eukaryotic wheat germ cell-free system.
This further highlights the usefulness of thioredoxin as a
fusion partner and the specificity of the antibodies we
obtained. To our knowledge this is the first report of
antibodies being produced against the GSL1 peptide.
Methods
Construction of recombinant expression vectors
The DNA coding sequence for the GSL1 (Genbank ac-
cession FJ195646) gene from potato was used for this
study. The DNA sequence encoding the GSL1 mature
peptide was designed with EcoRI restriction sites (GSL1)
at both the 5’ and 3’ends (Figure 1) to enable cloning
into the pET-32a expression vector (Novagen, CN
Biosciences, San Diego, CA, USA). The construct was de
novo synthesised by Genscript Corporation (Piscataway,
NJ, USA) and supplied in the plasmid pUC57 (desig-
nated pUC57-GSL1). Digestion of pUC57-GSL1 with
EcoRI produced a DNA fragment of approximately
200 bp which was then ligated into the vector pET-32a
using standard molecular biology techniques [28], result-
ing in the production of the E. coli expression vector
pET-32a+GSL1. Positive clones with the GSL1 gene in
the correct orientation were identified by PCR screening
using the sequencing primers GSL1 (5’GGGCATTTA
GACTTGCCCTTA3’) combined with the S.Tag primer
which binds just upstream of the multiple cloning site in
pET-32a (5’CGAACGCCAGCACATGGACA3’).
To enable recombinant expression of an N-terminally
his6-tagged GSL1 peptide in the wheat germ cell-free ex-
pression system, the GSL1 gene was PCR amplified from
the pUC57-GSL1 plasmid using the StSN1GWCHMP
For primer (5’GGGGACAAGTTTGTACAAAAAAGCA
GGCTATGCATCATCATCATCATCATGGTTCAAATT
TTTGTGATTCAAAGTGCAAGC3’) and the StSN1G
WCH Rev primer (5’GGGGACCACTTTGTACAAGA
AAGCTGGGTTCAAGGGCATTTAGACTTGCCCTTA
GAGTTC3’). The primers incorporate sequence encod-
ing an N-terminal his6 tag, as well as attB1 and attB2 se-
quences to enable Gateway cloning of the fragment intopDONR221 using the BP clonase II enzyme (Life Tech-
nologies, Carlsbad, CA, USA). The construct was then
transferred using the Gateway® system from this vector
into pEU-DEST [26] for wheat germ expression, using
the LR clonase II enzyme (Life Technologies) to create
the expression vector pEU-his6-GSL1.
Expression of his6-thioredoxin-GSL1 in E. coli
The plasmid pET-32a+GSL1 was transformed into the E.
coli strain BL21 (DE3), which contains a T7 RNA poly-
merase gene for inducible protein expression [29]. A
single transformed BL21 (DE3) colony was used to in-
oculate 50 mL LB broth containing 100 mg/L ampicillin
and incubated overnight at 30°C. Two mL of the over-
night culture were transferred into a flask containing
fresh 50 mL LB medium with 100 mg/L ampicillin. The
culture was grown with 200 rpm shaking at 37°C until
the OD (600 nm) reached 0.8. The culture was induced
by addition of 0.2 mL of 100 mM isopropyl-β-D-thio-
galactopyranoside (IPTG). Immediately prior to induc-
tion, 1 mL of culture was removed as the zero time-point
sample. One mL samples were removed 2 and 4 h after
induction. Each 1 mL sample of cells was pelleted in a
micro-centrifuge and the cells were washed with 1 mL of
phosphate-buffered saline (PBS), pelleted, and stored
at -20°C until further processing. For preparative-scale
experiments, the remaining 47 mL of the overnight cul-
ture was then transferred into a flask containing 1250 mL
of LB medium with 100 mg/L ampicillin, grown with
230 rpm at 37°C until an OD (600 nm) of 0.8 was
reached. Expression of his6-thioredoxin-GSL1 was in-
duced by the addition of 0.5 mM IPTG. Cells were
harvested at 2 h post-induction.
Purification of his6-thioredoxin-GSL1 fusion protein
Immobilised Metal Affinity Chromatography (IMAC)
purification [30] was used with modifications to purify
the his6-tagged fusion protein. The induced culture was
processed by centrifugation at 4,500 × g for 20 min at
10°C. The cell pellet was weighed and resuspended by
pipetting on ice in 2.2 mL/g pellet lysis buffer (0.1 M
HEPES, 0.5 M NaCl, 10% glycerol, 0.01 M imidazole,
supplemented with one tablet of Complete EDTA-free
protease inhibitor (Roche Diagnostics, Auckland, New
Zealand), and 2,000 U Benzonase per 100 mL buffer,
pH 8.0) and stored at -80°C. Tubes containing 10 mL –
12.5 mL thawed and pooled cell suspension were placed
in an ice bath and sonicated using a Branson Sonifier
250 (Branson, Danbury, CT, USA) on output setting five,
for 1 min 15 s per cycle. A total of three cycles were car-
ried out with a rest period of 2 min between cycles. The
lysate was centrifuged at 20,000 × g for 30 min at 4°C,
the supernatant was decanted and filtered through a
0.45 μm syringe filter (Pall Corporation, Cornwall, UK).
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away, NJ, USA) and a peristaltic pump were used to purify
the fusion protein. Eluted fractions were monitored at
A280nm using an ISCO UA-5 Absorbance Monitor and col-
lected with an ISCO Retriever II fraction collector (Isco,
NE, USA). The flow-rate was set to 1 mL/min for each
run. The column was equilibrated with 5 mL IMAC
wash1 buffer (0.02 M HEPES, 0.5 M NaCl, 10% glycerol,
0.01 M imidazole, pH 7.5) and loaded with the lysate. The
protein sample was loaded on the column, washed with
10 mL IMAC wash1 buffer followed by 6 mL IMAC
wash2 buffer (0.02 M HEPES, 0.5 M NaCl, 10% glycerol,
0.025 M imidazole, pH 7.5). Bound protein was eluted
from the column with 6 mL IMAC elution buffer (0.02 M
HEPES, 0.5 M NaCl, 10% glycerol, 0.5 M imidazole, pH 7.5)
as 0.5 mL aliquots. All steps were performed at 4°C.
After determining which fractions contained the fusion
protein by SDS-PAGE, those fractions containing low
amounts of protein were concentrated and desalted by
Microcon® centrifugal filter (Millipore, MA, USA) with a
molecular weight cut-off of 10 kDA. Following these
procedures, all fractions were pooled and placed into
pre-prepared dialysis tubing with a molecular weight
cut-off of 12 kDa. Protein was concentrated by placing
the dialysis tubing in a plastic tray and covering with
granular sucrose before incubation at 4°C overnight. The
protein in the tubing was subsequently equilibrated
three times in 2 L PBS for 2 h. The first PBS dialysis buf-
fer was supplemented with 125 mM imidazole to help
prevent protein precipitation. After a third dialysis using
PBS, the protein was transferred to 1.5 mL tubes and ap-
proximate total protein was determined by SDS-PAGE
followed by verification of protein content by western
blot analysis using anti-thioredoxin antibodies. The iso-
lated fusion protein was used as an antigen for injection
into rabbits, as previously described [31].
Wheat germ cell-free expression of his6-tagged GSL1
Wheat germ cell-free expression was performed using
the pEU-his6-GSL1 plasmid as template and the
WEPRO7240H kit (CellFree Sciences, Yokohama, Japan)
according to the manufacturers’ instructions. As this re-
quires transcription and translation to be carried out sep-
arately, 20 μL transcription reactions were set up and
incubated at 37 oC for 6 h. Translation reactions were set
up in individual wells of a 96-well microtiter plate using
10 μL of the transcription reaction mixed with 10 μL of the
WEPRO mix and 0.8 μL of creatine kinase then overlaid
with 206 μL of feeding solution. The reaction was incu-
bated at 15°C for ~20 h before placing the samples on ice.
SDS-PAGE and western blot analysis
SDS-PAGE analysis was performed essentially as de-
scribed previously using a 10–20 % Tris-Tricine/PeptideGel (Bio-Rad, Hercules, CA, USA) [25]. Protein was
transferred onto the PVDF membrane using the iBlot
gel transfer system (Life Technologies). For electrophor-
esis of protein produced in the wheat germ cell-free sys-
tem, protein was electrophoresed using a Surelock Mini
Cell (Life Technologies, Carlsbad, CA, USA), for 35 min
at 200 V. Thioredoxin containing protein bands were
visualised by incubation with the anti-thioredoxin primary
antibody produced in rabbit (Sigma St. Louis, MO, USA),
followed by the anti-rabbit-alkaline phosphatase second-
ary antibody (Sigma) and exposure to the chromogenic
BCIP®/NBT-Blue liquid substrate (Sigma) (Figure 2B).
GSL containing bands were visualised by incubation of
the blot with a 1:400 dilution of sera containing Rabbit
anti-GSL antibodies (raised in this study), followed by in-
cubation with the secondary antibody Immun-Star™ Goat
Anti-Rabbit (GAR)-HRP Conjugate (Bio-Rad) with a
1:100,000 dilution. Following the blots development, light
signals were captured on Lumi-Film Chemiluminescent
Detection Films (Bio-Rad) (Figure 4B).
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